The incidence of restenosis after a first successful percutaneous transluminal angioplasty of a native renal artery and the clinical and angiographic variables that may influence its occurrence were studied in 104 hypertensive patients. Angiograms obtained immediately before and after angioplasty and, in 92 patients, 8.8 ±6.0 months after angioplasty were interpreted separately by two observers. Stenosis severity was classified into five grades, and restenosis was defined by a stenosis one grade or more higher at follow-up than immediately after angioplasty. Interobserver concordance for etiology, stenosis grade, and other angiographic items yielded K coefficients in the range of 0328-0.942. Sessions were organized to reach a consensus in each case. Ostial stenoses were more frequent in patients with atheromatous stenoses, and branch stenoses were more frequent in those with fibromuscular dysplasia. There was no significant difference between the 15 patients (16%) with restenosis and those without concerning sex distribution, mean age, mean blood pressure, plasma creatinine level, and etiology distribution. Truncal stenoses were less prone to restenosis than ostial or branch stenoses (12% versus 35%, respectively; 95% confidence interval of difference, -0.6% to 47%). In patients with atheromatous stenoses, aortitis or aortic ectasia were associated with a high restenosis incidence (35% when present versus 8% when absent; 95% confidence interval of difference, 5% to 48%). In conclusion, restenosis was observed in one sixth of patients after a first successful renal angioplasty; its incidence was low in patients with truncal stenoses and high in those with severe aortic atheroma. Automated renal artery stenosis quantification methods are needed to standardize stenosis description. 
P ercutaneous transluminal angioplasty was first used in patients with renal artery stenosis in 1978 by Griintzig et al. 1 Since then, percutaneous transluminal renal angioplasty (PTRA) has become widely used for renal artery stenosis treatment 2 and has tended to replace surgical revascularization as the firstline treatment in hypertensive patients with main vessel stenosis due to atheroma or fibromuscular dysplasia. 3 The objectives of PTRA are the improvement of blood pressure (BP) control and renal function and, in the long term, the prevention of renal artery thrombosis. The patency of the artery subjected to PTRA is a prerequisite for realizing these objectives. Restenosis is therefore the main threat to lasting BP improvement and restored or maintained renal function after a successful PTRA. Whereas the clinical, angiographic, and procedural variables that are predictive of coronary restenosis after angioplasty have been extensively reviewed, 4 -6 little is known about the restenosis frequency or its associated factors in renovascular disease. In an attempt to further rationalize patient selection for PTRA, we performed this study to estimate the frequency of restenosis after a first successful PTRA and to determine the factors connected with stenosis recurrence.
Methods

Patient Selection
A first PTRA on a native renal artery was performed in 138 patients in our Hypertension Unit between January 1985 and December 1989. The decision to dilate was based on a >50% reduction in diameter of one or more renal arteries plus one or more of the following criteria: resistant hypertension, defined by a diastolic BP >94 mm Hg despite at least a bitherapy; renal artery thrombosis or diameter reduction >75%; or evidence for functional lateralization according to pyelography, renal scintigraphy, or renal vein-renin ratio. The patients included in the present study were those considered to be at risk for restenosis and for whom follow-up was possible. We therefore excluded patients living outside the Paris area (Paris itself plus the seven neighboring departments, an area including one fifth of the total French population; n = 15 patients) and all technical failures (stenosis catheterization impossible, absence of stenosis improvement, or thrombosis after PTRA; « = 16). In addition, we excluded two men harboring stenoses complicating radiation therapy (for metastatic nephroblastoma in one case and Hodgkin's disease in the other) and one woman with a stenosis caused by Takayasu's disease. Of the 104 eligible patients, two had had a very early follow-up angiogram (after 3 and 8 weeks, respectively), which showed no restenosis, and were not considered suitable for the present study, and 10 lacked angiographic follow-up. Of these, two patients did not accept a follow-up angiogram. The remaining eight patients were lost to our follow-up: We documented an uneventful outcome in three patients whose personal physician did not consider a repeat angiogram to be indicated and in another who returned to our clinic well controlled by a monotherapy 4 years after PTRA; the last four patients could not be traced. We were therefore able to include 92 complete medical records in the present analysis. Figure 1 provides a flowchart describing the selection process.
Before PTRA, all relevant patient historical, clinical, and biological data (including age, sex, known hypertension duration, smoking habits, BP, current treatment; clinical/ultrasonographic/radiological evidence of cardiovascular disease in sites other than the renal arteries; routine biological parameters) were recorded in a computerized data base as previously described. 7 Patients gave informed consent, and the procedures followed were in accordance with institutional guidelines.
Angioplasty Technique and Follow-up
Antihypertensive treatment was discontinued before PTRA to avoid an abrupt drop in BP after the procedure. All PTRAs were performed by the same physician (A.R.). A standard anterograde femoral artery puncture was performed with patients under local anesthesia, and a diagnostic catheter was advanced to just in front of the ostium of the stenotic renal artery to obtain a pre-PTRA angiogram. Stenosis catheterization was preceded by an intravenous heparin dose of 2,000-5,000 IU. The lesion was passed using a 5F catheter and a very soft guide wire, which was then replaced by a 35 Rosen heavy-duty guide. A 5F angioplasty catheter was slid over the guide, and the balloon was placed into the stenosis. The balloon diameter was equal to or slightly larger than the diameter of the renal artery, ranging from 5 to 7 mm for a main renal artery. The balloon was inflated with slowly increasing pressure until the "waist" on the balloon had disappeared. This pressure level was maintained for approximately 1 minute. The balloon catheter was withdrawn, and an angiogram was obtained with the guide wire still positioned through the stenosis. In the case of residual stenosis >30%, an additional dilatation using a balloon 1 mm larger was performed. In the case of obstructive parietal damage, an additional and longer (3-4 minutes) low pressure inflation was performed using the same balloon catheter. After all equipment had been withdrawn from the renal artery, a post-PTRA angiogram was obtained by injection into the aorta. After the procedure, most patients were maintained on aspirin, 100-500 mg daily, for an arbitrary period of 6 months.
All patients were given an appointment for a follow-up angiogram, generally 6-12 months after the PTRA. Interim follow-up included outpatient visits, usually 15 days after discharge and then every 2 months; plasma creatinine dosage at the first follow-up visit; and, when necessary, resumption or adaptation of antihypertensive treatment.
Angiographic Data and Criteria for Angioplasty Outcome
For each individual patient, only one artery on which PTRA was performed was considered. In patients who had had more than one dilatation between 1985 and 1989, only the first PTRA was included in the present analysis. The 300 sets of angiograms obtained immediately before PTRA (n = 104), immediately after PTRA (n = 104), and at follow-up (n=92) were blinded (date of acquisition, birth date, and patient's name), coded, and then read separately by two of us (P.-F.P., A.R.) in a random order. Each reader was unaware of the lesion to be dilated when interpreting pre-PTRA angiograms. The two or three different angiograms from a given patient were not read in the same session.
The following items were recorded: stenosis etiology, as suggested by renal artery and aortic views (atheromatous or fibromuscular); stenosis site (ostial, truncal, or branch stenosis); stenosis severity, classified into five grades based on the ratio of the narrowest stenosis diameter to the distal renal artery diameter measured just before its bifurcation (no lesion, stenosis <50%, 50-75%, >75%, thrombosis); stenosis length (<1, 1-2, or >2 times the distal renal artery diameter just before its bifurcation); presence of poststenotic dilatation (poststenotic diameter > 150% of the distal renal artery diameter just before its bifurcation); and the presence of severe aortitis, aortic ectasia, or both. In addition, the presence of significant PTRA-induced lesions, such as intimal flaps or subintimal contrast medium injection, was recorded. Restenosis was defined by a residual stenosis one grade higher on the follow-up angiogram than on the immediate post-PTRA angiogram.
Between-Reader Concordance
The concordance between readers was estimated with the K coefficient, 8 based on the first 178 consecutive angiograms in our series, which included 51 before PTRA, 64 after PTRA, and 63 follow-up angiograms. 'Includes two patients who had a follow-up angiogram 3 and 8 weeks, respectively, after PTRA (no restenosis) and who were not considered for the study of restenosis.
tlncludes one patient with a solitary kidney. Severity of stenosis subjected to PTRA.
The K coefficient for etiology (readers being blinded for age, sex, and clinical context) was 0.677; for the presence of severe aortitis, aortic ectasia, or both, the coefficient was 0.942. The K coefficients for stenosis grading in pre-PTRA, post-PTRA, and follow-up angiograms were 0.476, 0.328, and 0.401, respectively. Sessions with the two readers were organized to review the discrepant readings. A consensus was reached in all cases, and the data presented in "Results" reflect between-reader agreement.
Statistical Analysis
Two sets of criteria were considered as candidate restenosis predictors. Primary criteria were derived from historical data and stenosis anatomy and included age and sex; known hypertension duration; the nature of current treatment before PTRA; smoking habits; serum cholesterol levels; the cause of the arterial disease; presence or absence of symptomatic extrarenal arterial disease; presence or absence of bilateral stenosis defined by a stenosis >50% on the opposite renal artery; stenosis site, severity, and length before PTRA; and the presence of severe infrarenal aortitis, aortic ectasia, or both. Secondary criteria were obtained after PTRA and included the presence of significant PTRA-induced lesions and residual stenosis severity.
Values are shown as mean±l SD. For main evaluational criteria, percentage differences between groups are given with the 95% confidence interval (95% CI).
Patients with or without restenosis were compared using a t test for quantitative variables and either a x 2 test or a Fisher's exact test for qualitative variables. 8 All calculations were performed with SAS statistical software (version 6.0, Cary, N.C.) on a VAX computer. A value of /?<0.05 was considered statistically significant.
Results
In our group of 104 eligible patients, there was no statistical difference between those patients with a follow-up angiogram (n=92) and those without («=12) for parameters such as mean age, hypertension duration, BP, creatinine level, sex distribution, and stenosis etiology and location (Table 1) . Similarly, there were no significant between-group differences regarding stenosis severity before or after PTRA: For the groups with and without follow-up angiography, respectively, pre-PTRA stenoses >75% were present in 68% and 85% of patients (p=0.34 by Fisher's exact test), and post-PTRA stenoses 2:50% were present in 5% and 8% (p=0.9 by Fisher's exact test).
PTRA procedural complications occurred in seven patients with complete follow-up. Four patients (three with fibromuscular and one with atheromatous stenoses) with an otherwise successful PTRA developed small segmental renal infarctions with no increase in serum creatinine levels. Three other patients aged 71, 73, and 77 years exhibited access site hematomas that resolved spontaneously; transfusion was not necessary, •Stenosis characteristics concern the stenosis in artery subjected to angioplasty. tStenosis length could not be determined in two patients.
but a few additional days of hospitalization were required. The 92 patients with angiographic follow-up underwent this procedure 8.8 ±6.0 months after PTRA, with the use of intra-arterial (n=71) or intravenous (n=21) digitized angiography. The time interval range from PTRA to follow-up angiography was 3-25 months, 80% of the patients having a time interval in the range of 5-15 months. Table 2 shows the entry characteristics for this group of patients, consisting of 59 atheromatous and 33 fibromuscular stenoses. As expected, the patients with atheromatous stenoses were more frequently male, were older, had a longer known hypertension duration, and had higher levels of systolic BP, plasma cholesterol, and creatinine than those with fibromuscular stenoses. Although the proportion of patients with any smoking history (present plus exsmokers) was similar in the atheromatous and fibromuscular groups (61% and 58%, respectively), the proportion of current smokers was lower in patients with atheroma than in those with fibromuscular dysplasia (20% versus 42%,/?=0.02), this difference reflected a higher number of quitters in patients with atheroma. Ostial stenoses were more frequent in atheroma and branch stenoses more frequent in fibromuscular dysplasia, the latter being associated more frequently with stenoses exceeding two artery diameters. There was no significant difference in the etiology distribution between different grades of stenosis severity. For the groups with atheromatous and fibrodysplastic stenoses, respectively, pre-PTRA stenoses >75% were present in 63% and 79% of cases (p=0.11 by Fisher's exact test), and post-PTRA residual stenoses ^50% were present in 9% and 0% (p=0.11 by Fisher's exact test).
Of the 92 patients with angiographic follow-up, 15 (16%) exhibited restenoses and 77 did not; the mean time to follow-up angiogram was 266 and 264 days, respectively. Tables 3 and 4 compare the distributions of candidate restenosis predictors derived from our primary criteria in those patients in whom restenosis 'Presence or absence of restenosis was judged from a single artery; in patients with bilateral stenoses, the analysis dealt with the first artery subjected to angioplasty. tStenosis length could not be determined in two patients.
subsequently developed and in those in whom it did not. As shown in Table 3 , sex distribution, smoking habits, mean age, known hypertension duration, and mean levels of BP, plasma cholesterol, and creatinine did not differ significantly between patients with or without restenosis. There was no significant difference between the restenosis rate for the two etiologies: 19% and 12% for atheromatous and fibromuscular disease, respectively (95% CI of difference, -8.4% to 21.4%). Among the initial stenosis characteristics, only the site of the lesion subjected to PTRA was associated with subsequent restenosis: truncal stenoses were less prone to restenosis than ostial or branch stenoses (12% versus 35%; 95% CI of difference, -0.6% to 47%). Secondary criteria, i.e., the presence of significant PTRA-induced lesions or residual stenosis severity, were not associated with restenosis occurrence. Table 4 shows that, in patients with atheromatous stenosis, subsequent restenosis was associated with lower initial diastolic BP levels (p=0.03), more advanced age, and more frequent high grade (£75%) and ostial stenoses, although the differences in these last criteria did not reach statistical significance. Although the presence of diffuse atheromatous lesions, reflected by extrarenal arterial disease, was not associated with restenosis occurrence, patients with severe aortitis or infrarenal aortic ectasia exhibited a significantly higher restenosis rate (35% when present versus 8% when absent; 95% CI of difference, 5% to 48%).
Discussion
Although a relatively large number of articles have reported the long-term results of PTRA, little is known about the restenosis rate after the procedure. KremerHovinga et al 9 reported the frequency of restenosis after successful PTRA at 42% in atheromatous and 22% in fibromuscular stenoses, but they did not define restenosis and derived their restenosis rate estimations from only 24 patients with atheroma and nine with fibromuscular dysplasia. Among the published series describing the long-term outcome of at least 50 patients who had undergone a successful PTRA, 10 -20 several did not report the results of follow-up angiography or mentioned that follow-up angiography was performed in only a minority of patients, 10 ' 11 ' 13 -17 -20 generally selected on the basis of recurrent hypertension. A few series 12 -1819 stated that angiography was a standard follow-up procedure; unfortunately, they did not permit calculation of the restenosis rate, because they did not report the precise number of patients with successful angioplasty who had follow-up angiography and did not give a clear definition of restenosis. None of these •Stenosis length could not be determined in two patients.
reports included an analysis of factors related to restenosis occurrence.
Restenosis has been considered the greatest challenge facing coronary angioplasty 21 and is considered to affect at least one third of cases. This explains the large bulk of data concerning the pathophysiology, risk factors, and attempts at prevention of restenoses after coronary angioplasty. 4 -6 -22 However, these data cannot be extrapolated to renal artery restenosis, because renal arteries differ from coronary arteries in dimension and physiology and may be affected by stenoses of diverse etiology. Renal artery diameter and flow are larger than those of coronary arteries. Blood flow is maximal during systole in the renal circulation and during diastole in the coronary circulation. Renal artery stenoses may be either atheromatous or fibromuscular, with approximate prevalences of two of three and one of three, respectively, whereas virtually all coronary stenoses are atheromatous. Atheromatous renal artery stenoses are frequently ostial or paraostial, affecting a conic segment of this large artery in connection with the aortic wall, whereas most coronary stenoses affect the trunk or bifurcation of the affected arteries. The practical consequence of this is that the current technology used to quantify coronary stenosis cannot be accurately applied to many renal artery stenoses.
We report here that, after renal artery angioplasty, restenosis could affect one in six patients, that truncal stenoses were less prone to restenosis than ostial or branch stenoses, and that in patients with atheromatous stenoses, aortitis or infrarenal aortic ectasia were associated with a high restenosis rate. To reach these conclusions, we retrieved the records of all patients who had undergone a PTRA from 1985 to 1989 from an exhaustive data base 7 in which items including candidate restenosis risk indicators were entered prospectively. The BP outcome of many of these patients has been reported elsewhere 19 and is outside the scope of this study. Only patients at risk of restenosis were included, and therefore those with initial PTRA failure were excluded. We excluded patients with PTRA of a previous restenosis and of stenoses affecting a renal graft artery or complicating radiation therapy or Takayasu's disease to limit the variability in outcome linked to the underlying disease. The availability of angiographic follow-up is a prerequisite condition for the study of restenosis; we therefore did not include patients referred from distant towns in whom follow-up was not feasible. These exclusion criteria left 104 patients in whom clinical and angiographic follow-up was feasible and planned. As shown in Figure 1 , angiographic follow-up was not available in 10 patients, and, in another two patients, repeat angiogram was performed within 2 months after PTRA, a time interval too short to detect the process of restenosis. 22 9 after PTRA (77%). We established that our imperfect angiographic follow-up was not associated with a particular clinical profile and therefore did not reflect a selection bias, e.g., difference in age, etiology, initial BP or renal function, or gross difference in the immediate PTRA outcome (Table 1) . Among the patients who underwent a follow-up angiogram, there was no relation between restenosis occurrence and the time lag between PTRA and angiographic follow-up, because this time interval was virtually identical in patients who subsequently exhibited a restenosis and those who did not (266 and 264 days, respectively).
There is no single accepted angiographic criterion for restenosis after coronary angioplasty, and a fortiori, after PTRA. Within a given group of patients, the method used to estimate the initial stenosis severity and the arbitrary threshold defining a significant increase in stenosis severity at follow-up are both expected to influence the apparent restenosis incidence. Digital quantification of coronary artery stenosis has been shown to yield a better reproducibility than visual interpretation, which leads to a systematic overestimation of stenoses in the intermediate (50-75%) range. 23 Using either a visual or a quantitative automated evaluation of coronary angiograms, Serruys et al 22 emphasized the better reproducibility of automatic assessment of coronary diameter, enabling an absolute definition of restenosis. Although automated computer assessment of stenoses from digital subtraction angiographic images has been carefully validated in the coronary circulation, 24 no validated method exists of automated quantification for renal artery stenoses. From the present series, we felt that the mathematical models appropriate for coronary artery stenosis quantification would not be appropriate in either atheromatous or fibrodysplastic renal artery stenoses. In the former, the main difficulty would arise from the relatively high frequency (36%) of poststenotic dilatations exceeding 150% of the reference diameter, and in the latter, from the usual aspect of thin, multiple, consecutive diaphragms encroaching on the lumen. We therefore relied on the visual estimation of stenosis severity.
After a preliminary test run on a first set of angiograms, we agreed on the method for measuring the narrowest and "reference" arterial diameters and on common definitions for stenosis grade, stenosis length, and poststenotic dilatation. Two of us blinded and coded the 302 angiograms of our patient population, and two others interpreted all the angiograms, separately and blinded for the sequence of angiograms (before PTRA, after PTRA, or at follow-up) and for the clinical context. Between-reader concordance was estimated from a sample of 178 angiograms, showing a significant, yet less than optimal, reproducibility for stenosis grade (see "Methods"). Discrepancies regarding etiology were easily overcome when the readers were unblinded for age, sex, and clinical history of extrarenal arterial disease. In virtually all cases, the source of discrepancy regarding stenosis grade was the choice of the site where the reference diameter was measured, rather than the measurement of the stenosis itself. The blinded assessment was performed separately for all angiograms, but consensus sessions were subsequently organized to resolve the discrepancies.
We used a change of one stenosis grade as a criterion for restenosis because it was the minimum change we could detect with confidence using the visual method. The sensitivity of this criterion is expected to influence the rate of restenosis and also the apparent association with predictors: the higher the sensitivity of this restenosis criterion, the higher its apparent incidence and the lower its correlation with predictors. We may have overestimated our capacity to detect changes in stenosis grade, i.e., the sensitivity of this criterion in detecting true restenosis, and therefore may have overestimated the true incidence of restenosis. The opposite may also be true; i.e., this fairly crude criterion might have led to an underestimation of the true incidence of restenosis. This difficulty was demonstrated by Serruys et al, 22 who, testing a set of six different criteria, obtained six different estimates of the restenosis rate after coronary artery angioplasty within the same group of patients. Even bearing these limitations in mind, we found that the restenosis incidence after PTRA (16%) was clearly less than that after coronary artery angioplasty (roughly 30% 22 ).
The present estimation of the restenosis incidence after a successful PTRA in hypertensive patients with atheromatous stenoses, i.e., 19%, could also explain a significant proportion of the cited hypertension failure rate (no improvement in BP after a successful PTRA) of 30% in these patients. 2 Admittedly, several factors other than renal artery patency may influence the BP outcome after PTRA. These figures suggest, however, that angiographic follow-up should be routinely performed using intravenous or intra-arterial digitized subtraction angiography, particularly in prospective trials of PTRA and in the prospective evaluation of diagnostic tests for renovascular hypertension.
We found that few parameters were significantly associated with the risk of subsequent restenosis, either because restenosis is unpredictable or, most likely, because of the limited power of our study. For instance, there was not a statistically significant difference in the restenosis rate between atheromatous and fibrodysplastic stenoses (19% and 12%, respectively; 95% CI of difference, -8.4% to 21.4%). The observed tendency toward a lower incidence of restenosis in fibrodysplastic than in atheromatous stenoses may be either spurious or real but not statistically significant (the "f) error"). Among the predictors tested, only two appeared to be associated with restenosis: severe aortic atheromatous disease and nontruncal stenosis. The nontruncal stenoses represent a composite criterion involving branch stenoses (all dysplastic) and ostial stenoses (mainly atheromatous). Stenosis separation into truncal and nontruncal groups was based on purely pragmatic reasons: truncal stenoses are usually easier to dilate. This study found that truncal stenoses were associated with a lower incidence of restenosis at a marginal level of significance. Finally, restenosis was most strongly associated with the presence of aortitis, aortic ectasia, or both. Confirmation of the present findings should either involve a much larger number of patients or, preferably, use a more sensitive method of renal artery diameter quantification.
In summary, restenosis is observed in one sixth of patients after a first successful renal angioplasty. Patients with truncal stenoses are better candidates for PTRA than those with ostial lesions (mainly atheromatous) or branch stenoses (mainly fibrodysplastic). PTRA should be considered cautiously in patients with severe aortic atheroma, because they are at high risk of immediate complications and of subsequent restenosis. In addition, the limited precision and the complicated performance of visual renal artery assessment clearly emphasize the need for further research in automated renal artery stenosis quantification.
